Editas Medicine (EDIT) Research & Development (2015 - 2025)
Editas Medicine (EDIT) reported Research & Development of $19.8 million for Q3 2025, down 58.49% year-over-year from $47.6 million in Q3 2024, and up 22.21% on a QoQ basis from $16.2 million in Q2 2025.
Editas Medicine (EDIT) has 11 years of Research & Development data on file, last reported at $19.8 million in Q3 2025.
- Quarterly Research & Development fell 58.49% year-over-year to $19.8 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $111.2 million (down 49.52% YoY) and the FY2024 annual result came in at $199.2 million, up 12.16% from the prior year.
- Research & Development rose to $19.8 million in Q3 2025 per EDIT's latest filing, from $16.2 million in the prior quarter.
- Across five years, Research & Development topped out at $69.6 million in Q4 2023 and bottomed at $16.2 million in Q2 2025.
- The 5-year median for Research & Development is $40.5 million (2023), against an average of $39.8 million.
- The widest annual swing landed in 2024, when Research & Development surged 82.04%; it then slumped 70.15% in 2025.
- Tracing EDIT's Research & Development over 5 years: stood at $37.6 million in 2021, then jumped by 38.47% to $52.0 million in 2022, then surged by 33.77% to $69.6 million in 2023, then slumped by 30.11% to $48.6 million in 2024, then sank by 59.32% to $19.8 million in 2025.
- Per Business Quant, the three latest EDIT Research & Development figures stand at $19.8 million (Q3 2025), $16.2 million (Q2 2025), and $26.6 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 19.78 Mn |
| Jun 30, 2025 | 16.18 Mn |
| Mar 31, 2025 | 26.59 Mn |
| Dec 31, 2024 | 48.61 Mn |
| Sep 30, 2024 | 47.64 Mn |
| Jun 30, 2024 | 54.21 Mn |
| Mar 31, 2024 | 48.79 Mn |
| Dec 31, 2023 | 69.56 Mn |
| Sep 30, 2023 | 40.51 Mn |
| Jun 30, 2023 | 29.78 Mn |
| Mar 31, 2023 | 37.80 Mn |
| Dec 31, 2022 | 52.00 Mn |
| Sep 30, 2022 | 41.33 Mn |
| Jun 30, 2022 | 43.66 Mn |
| Mar 31, 2022 | 37.98 Mn |
| Dec 31, 2021 | 37.55 Mn |
| Sep 30, 2021 | 29.27 Mn |
| Jun 30, 2021 | 33.75 Mn |
| Mar 31, 2021 | 41.94 Mn |
| Dec 31, 2020 | 61.50 Mn |
| Sep 30, 2020 | 33.92 Mn |
| Jun 30, 2020 | 28.01 Mn |
| Mar 31, 2020 | 34.57 Mn |
| Dec 31, 2019 | 34.79 Mn |
| Sep 30, 2019 | 22.70 Mn |
| Jun 30, 2019 | 23.57 Mn |
| Mar 31, 2019 | 15.84 Mn |
| Dec 31, 2018 | 19.19 Mn |
| Sep 30, 2018 | 17.44 Mn |
| Jun 30, 2018 | 32.72 Mn |
| Mar 31, 2018 | 21.30 Mn |
| Sep 30, 2017 | 20.40 Mn |
| Jun 30, 2017 | 17.32 Mn |
| Mar 31, 2017 | 19.02 Mn |
| Dec 31, 2016 | 16.50 Mn |
| Sep 30, 2016 | 10.83 Mn |
| Jun 30, 2016 | 10.43 Mn |
| Mar 31, 2016 | 8.88 Mn |
| Dec 31, 2015 | 5.83 Mn |
| Sep 30, 2015 | 3.85 Mn |
| Jun 30, 2015 | 7.28 Mn |
| Mar 31, 2015 | 1.89 Mn |